Sign In
Buy DHR
$178.08
+1.97 (+1.12%)
At Close: Jun 03, 2026
Clearstead Advisors LLC Grows Stock Position in Danaher Corporation $DHR
06:12am, Monday, 23'rd Feb 2026
Clearstead Advisors LLC grew its position in shares of Danaher Corporation (NYSE: DHR) by 4.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission
Danaher Corporation $DHR Position Boosted by Avalon Trust Co
04:05am, Monday, 23'rd Feb 2026
Avalon Trust Co lifted its holdings in Danaher Corporation (NYSE: DHR) by 5.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
Beverly Hills Private Wealth LLC Acquires Shares of 3,382 Danaher Corporation $DHR
04:18am, Saturday, 21'st Feb 2026
Beverly Hills Private Wealth LLC bought a new position in shares of Danaher Corporation (NYSE: DHR) during the third quarter, according to its most recent Form 13F filing with the Securities and Excha
Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
08:30pm, Wednesday, 18'th Feb 2026
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of M
Danaher's $9.9B Masimo Deal Marks One of 2026's Largest Medtech Buyouts
08:50am, Wednesday, 18'th Feb 2026
Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share.
Daniel Loeb's Strategic Moves: Flutter Entertainment PLC Exits with -3.17% Impact
06:03pm, Tuesday, 17'th Feb 2026
Exploring the Latest 13F Filing and Investment Adjustments Daniel Loeb (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, pr
Danaher to Acquire Masimo in $9.9 Billion All-Cash Deal
11:14am, Tuesday, 17'th Feb 2026
Danaher has announced its plan to acquire Masimo (MASI) for $180 per share in an all-cash transaction. This represents a 38% premium over Masimo's previous clos
Shares of Masimo, Danaher Moving on Acquisition Buzz
10:32am, Tuesday, 17'th Feb 2026
Medical technology stock Masimo Corp (NASDAQ:MASI) is soaring today, last seen up 34.3% to trade at $174.78, after reports that the company is nearing an agreement to be acquired by Danaher Corp (NYS
Danaher to acquire Masimo in $9.9B all-cash deal
09:40am, Tuesday, 17'th Feb 2026
Danaher Corporation (NYSE:DHR) announced it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) in an all-cash transaction valued at approximately $9.9 billion, as the
Danaher to buy Masimo for $9.9 billion
08:04am, Tuesday, 17'th Feb 2026
Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio.
Masimo to be Acquired by Danaher for $180.00 Per Share
08:02am, Tuesday, 17'th Feb 2026
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which
Danaher To Acquire Masimo Corporation
08:00am, Tuesday, 17'th Feb 2026
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo
First Look: WBD waiver; Ackman's Meta bet; Ford-China JV
07:39am, Tuesday, 17'th Feb 2026
Stock News WBD reopens rival talks under Netflix waiver: Warner Bros. Discovery (WBD) received a seven-day waiver from Netflix (NFLX) to resume talks with Param
Wall Street Breakfast Podcast: Masimo Jumps As Danaher Nears $10B Deal
06:49am, Tuesday, 17'th Feb 2026
Danaher (DHR) is nearing a ~$10B acquisition of Masimo (MASI), representing a significant premium to MASI's prior $7B market cap. Elliott Investment Management has built a >10% stake in Norwegian Crui
Danaher Strikes $10 Billion Deal for Masimo
06:09am, Tuesday, 17'th Feb 2026
The medical-device maker is expected to operate as a stand-alone company within Danaher's Diagnostics segment.
